DocWire News Editors

DocwireNews

Immunoglobin A (IgA) nephropathy is the most common glomerulonephritis. It occurs from a process wherein the kidneys suffer systemic damage. Synthesis and binding of antibodies directed against galactose deficient IgA1 cause the formation of immune complexes; a formation which activates mesangial cells, inducing proliferation and secretion of the extracellular matrix, cytokines, and chemokines, which results in kidney injury.&nbsp;The endothelial (ET) family consists of three 21 amino acid peptides (ET-1, ET-2, and ET-3). ET-1 plays the biggest role in kidney functionality and disease because its binding effects, specifically the receptor isoform ETB, promotes tissue injury and scarring. Similarly, angiotensin II (ANG II), a primary active peptide of the renin-angiotensin-aldosterone system (RAAS), has well established actions in the kidney and plays a critical role in renal pathophysiology. ET-1 signalling works in concert with ANG II signalling to amplify the ongoing inflammatory cytokine response and worsen glomerular injury and proteinuria, driving further tubular damage, which results in a progressive decline in kidney function.&nbsp;ANG II stimulates ET-1 release and expression in renal cells, while ET-1 mediates certain actions of ANG II. ANG II-dependent increases in ET-1 contribute to the vasoconstrictor effects of ANG II in vitro in isolated vascular preparations, while ET receptor blockade can inhibit the acute vasoconstrictor responses to ANG in vivo. Despite their obvious tandem role, it remains unclear whether ET-1 stimulates ANG II in nonvascular and renal cells.&nbsp;The major impact of ET-1 and ANG II includes glomerulosclerosis via mesangial cell proliferation, extracellular matrix production, podocyte cytoskeletal alterations, and podocyte loss, leading to increased glomerular permeability and proteinuria, and ultimately causing the progression of IgA nephropathy. Moreover, both pathways augment inflammation and fibrosis in the tubulointerstitial compartment as well as vasoconstriction and endothelial dysfunction of renal blood vessels.&nbsp;A potential remedy to the effect of ANG II and ET-1 is the development of dual ETAR and AT1R as therapeutic targets, a combination of individual receptor blockers. It has been posited that merging the structural elements of these two antagonists may yield a compound with dual activity for both receptors, which in turn may slow IgA nephropathy progression and reduce proteinuria.&nbsp;References: Benigni A, et al. Pediatr Nephrol 2021; 36: 763&ndash;775; Kohan DE &amp; Barton M. Kidney Int 2014; 86:896&ndash;904

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Latest News

How do the ET-1- and Ang II-Mediated Signalling Pathways Work in Tandem in the Pathophysiology and Progression of IgA Nephropathy?

Nephrology Times

Immunoglobin A (IgA) nephropathy is the most common glomerulonephritis. It occurs from a process wherein the kidneys suffer systemic damage. Synthesis and binding of ...

How do the ET-1- and Ang II-Mediated Signalling Pathways Work in Tandem in the Pathophysiology and

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe